Kringle Pharma, Inc.
Research Kringle Pharma, Inc. (4884.T) on Bullrun: market cap JPY 4.96B. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- Ticker4884.T
- ExchangeTSE
- CountryJapan
- SectorHealthcare
- IndustryBiotechnology
- CurrencyJPY
- Market capJPY 4.96B
- Financial periodFY2025
- RevenueJPY 72.22M
- Revenue growth-9.8%
- Net income-JPY 916.26M
- Free cash flow-JPY 755.78M
- Gross margin100.0%
Valuation Snapshot
latest market cap is JPY 4.96B.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | JPY 72.22M | -JPY 916.26M | -JPY 755.78M | 100.0% | -133.92 | JPY 1.62B | n/a | JPY 1.31B |
| FY2024 | JPY 80.04M | -JPY 756.45M | -JPY 661.17M | 100.0% | -118.21 | JPY 2.31B | n/a | JPY 2.11B |
| FY2023 | JPY 69.25M | -JPY 854.15M | -JPY 689.10M | 100.0% | -158.46 | JPY 2.14B | n/a | JPY 2.02B |
| FY2022 | JPY 391.83M | -JPY 331.83M | JPY 15.80M | 77.4% | -68.33 | JPY 2.76B | n/a | JPY 2.79B |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-18 | JPY 4.96B | n/a | n/a | 0 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 0 JPY.
About Kringle Pharma, Inc.
Kringle Pharma, Inc. engages in research and develops therapeutic agents for the treatment of intractable diseases in Japan. The company develops HGF products for the treatment of acute spinal cord injury, amyotrophic lateral sclerosis, vocal fold scar, and acute kidney injury. Kringle Pharma, Inc. was incorporated in 2001 and is based in Kita, Japan.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Kringle Pharma, Inc.'s market cap?
Kringle Pharma, Inc.'s market capitalization is JPY 4.96B.
What does Kringle Pharma, Inc. do?
Kringle Pharma, Inc. engages in research and develops therapeutic agents for the treatment of intractable diseases in Japan. The company develops HGF products for the treatment of acute spinal cord injury, amyotrophic lateral sclerosis, vocal fold scar, and acute kidney injury. Kringle Pharma, Inc. was incorporated in 2001 and is based in Kita, Japan.